X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Featured

Nasal Spray Could Lower Risk Of Opioid Addiction

Content Team by Content Team
10th February 2018
in Featured, Manufacturing, Press Statements

The animal study tested whether using nanotechnology enables the exclusive delivery of the drug into the brain and causes analgesia (pain relief). During the test, rats were given doses of NM0127 and their response to being placed on a hot plate was monitored.

If successful in humans, this method of pain relief could offer a safer alternative to synthetic opioids, where there is risk of overdose when the body becomes tolerant. The researchers found that the animals did not build up tolerance to the natural opioid over time, lowering risk of overdose.

The delivery of natural opioids is challenging as they are broken down by the liver and must cross the blood-brain barrier when injected. However, when the researchers encapsulated the opioids in nanoparticles, which were then administered intranasally, they could be delivered straight to receptors in the brain.

There is also evidence to suggest that enkephalin administered this way could be less addictive than injected opioids, but further research is needed.

Professor Ijeoma Uchegbu, one of the study authors and professor of pharmaceutical nanoscience at University College London told Pharmaceutical Technology: “There was no evidence that the rats sought out the drug as a reward, which suggests that the drug was not addictive. We would need to test whether patients experience euphoria after using the nasal spray in order to test this further.”

Chronic pain affects 19% of European adults, with nearly half being poorly managed by current therapies. With 115 people dying from drug overdose every day in the US, the new treatment could offer an alternative to highly addictive painkillers such as synthetic opioids.

The researchers are now raising funds for the first clinical trial in humans and hope that it may eventually be used to offer pain relief for patients with bone cancer.

“The main indication would be for breakthrough pain in patients with cancer, but it could also be used with those with moderate to severe pain,” said Uchegbu.

According to Uchegbu, the researchers are currently in talks with a number of commercial partners to progress with further research

Previous Post

Ablynx Enters €3.9bn Acquisition Deal With Sanofi

Next Post

Sanofi, DNDi Seek EMA Review For Sleeping Sickness Drug

Related Posts

Cathay Cargo signs global airline partnership with Tower Cold Chain
Packaging & Logistic

Cathay Cargo signs global airline partnership with Tower Cold Chain

31st March 2023
Featured

SVB Collapse And Its Implications On Biotechnology Sector

18th March 2023
Drug Development

Cell And Gene Therapy Boost With Novel UK Biotech Centres

18th March 2023
Featured

US President Looks To Double The Drugs For Price Negotiation

18th March 2023
Pharmapack 2023 a pivotal moment for sustainability in drug delivery and packaging
Europe

Pharmapack 2023 a pivotal moment for sustainability in drug delivery and packaging

3rd March 2023
$118bn Sales By 2026 Is What Japanese Pharma Can Expect
Featured

$118bn Sales By 2026 Is What Japanese Pharma Can Expect

2nd March 2023
Next Post

Sanofi, DNDi Seek EMA Review For Sleeping Sickness Drug

Latest News

Cathay Cargo signs global airline partnership with Tower Cold Chain
Packaging & Logistic

Cathay Cargo signs global airline partnership with Tower Cold Chain

31st March 2023
Quotient Sciences completes integration of drug substance into Translational Pharmaceutics Platform
Facilities & Operation

£277m Funding Set To Benefit UK Life Sciences Manufacturing

31st March 2023
Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In